image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Babcock International - Large reduction in net debt from £629m to £288m

February 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • BAB
  • Price:
  • 442p
Babcock’s H1 results beat expectations with EBIT profit up 27% (5% above forecast) to £154m on sales that rose 13% to £2,177m. The beat was put down to new infrastructure work on new facilities to accommodate the UK’s growing fleet of nuclear-powered submarines. The contract backlog stood at £9.3bn but doesn’t include a little over £3bn future work through framework agreements. Clearly, CEO David Lockwood’s root and branch restructuring and disposal program has had the desired effect as aided by a licence fee from Poland for three frigates (estimated to be £10m-£15m), net debt impressively fell from £629m to £288m with net debt / EBITDA now just 1.1x. Also encouraging was a reduction in the actuarial pension deficit from £400m to c. £300 ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author